Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB) will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on May 18 at 4:15 p.m. ET. A live audio webcast can be accessed on their website under the 'Investors and News' section, with a replay available for 21 days post-event. Seres Therapeutics is pioneering microbiome therapeutics with its SER-109 program, showing promising results for recurrent C. difficile infection, and has received Breakthrough Therapy and Orphan Drug designations from the FDA. The company is also advancing programs for ulcerative colitis and gastrointestinal infections.
- None.
- None.
Seres Therapeutics, Inc., (Nasdaq: MCRB), today announced that management will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on Tuesday, May 18 at 4:15 p.m. ET.
A live audio webcast of the panel will be available under the “Investors and News” section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designations from the FDA and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis, and plans to initiate a clinical program with SER-155 to prevent mortality due to gastrointestinal infections, bacteremia and graft versus host disease. For more information, please visit www.serestherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005069/en/
FAQ
What is Seres Therapeutics' stock symbol?
When will Seres Therapeutics participate in the RBC Capital Markets conference?
How can I listen to the Seres Therapeutics panel discussion?
What is the primary focus of Seres Therapeutics?
What designations has the SER-109 program received from the FDA?
